# Agape ATP Corp.

**ATPC**

Nasdaq; healthcare; SIC 8000, Services-Health Services; CIK 0001713210

**B**

**second fifth of 370 graded peers in healthcare**

rank 105 of 370; percentile 28.2; sampling error 2.5 points; lower is stronger

A B C D E

**B, the elk**



| Scoreboard | |
|---|---|
| **Profitability** | D/E<br>percentile 81.2 |
| **Solvency** | A<br>percentile 8.8 |
| **Growth and financing** | B<br>percentile 32.6 |
| **Reliability** | 0.83 AUC<br>filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025 |
| **Peer failure rate** | 1.07% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $12.5M to $120M assets<br>total assets $24.6M |
| **Standard universe** | inside<br>revenue above $1M and assets above $10M |
| **Warnings** | late filer<br>not computable: short runway, distress, fortress balance sheet |
| **Inputs computable** | 8 of 14 |
| **Graded from** | filings received through Apr 13, 2026<br>207 days before the rescan; latest periodic filing 10-Q received Aug 14, 2026 |
| **Last close** | $1.24<br>2026-11-03; market equity $1.2M; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Apr 13, 2026*

ATP Corporation, a Nevada corporation ("the Company") was incorporated under the laws of the State of Nevada on June 1, 2016. ATP Corporation operates through its subsidiaries, namely, Agape ATP Corporation ("AATP LB"), a company incorporated in Labuan, Malaysia, and Agape Superior Living Sdn. Bhd. ("ASL"), a company incorporated in Malaysia on August 8, 2003. LB is an investment holding company with 100% equity interest in Agape ATP International Holding Limited ("AATP HK"), a company May 8, 2020, the Company entered into a Share Exchange Agreement with Mr.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 81.2** | | | | | | |
| Gross profitability | 3.4% | 32.3% | | 87.4 | 365 | 2025-12-31 |
| Return on invested capital | not computable | 9.3% | | | | |
| *one or more required annual facts are missing* | | | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | |
|---|---|---|---|---|---|
| Accruals ratio | 1.0% | (6.6%) | 82.6 | 802 | 2025-12-31 |
| Gross margin stability, five years | 5.7 pts | 2.8 pts | 73.4 | 242 | 2025-12-31 |
| **Solvency, sleeve percentile 8.8** | | | | | |
| Twelve-month failure probability | not computable | 0.07% | | | |
| *latest liabilities, cash plus short-term investments, book equity, and shares are required* | | | | | |
| Altman Z double-prime | 14.37 | (0.37) | 5.0 | 747 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.82x | | | |
| *one or more required annual facts are missing* | | | | | |
| Interest coverage | not computable | (4.51x) | | | |
| *one or more required annual facts are missing* | | | | | |
| Current ratio | 11.82x | 2.94x | 12.7 | 828 | 2025-12-31 |
| **Growth and financing, sleeve percentile 32.6** | | | | | |
| Revenue growth, three-year compound | (6.4%) | 10.0% | 82.5 | 412 | 2025-12-31 |
| Free cash flow growth, three-year compound | not computable | 10.9% | | | |
| *four consecutive annual FCF observations are required; found 2* | | | | | |
| Reinvestment rate | not computable | 37.1% | | | |
| *pretax income must exceed the validity floor and imply a 0%-100% tax rate* | | | | | |
| Asset growth, three years | 106.5% | 2.2% | 1.9 | 696 | 2025-12-31 |
| Net share issuance, one year | 0.05% | 2.5% | 13.4 | 630 | 2026-03-17 |

## Warnings

*1 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Late filer | found 1 NT 10-K/Q filings in the last eight quarters |

## Among 370 peers

*healthcare; letters are fifths of this list*




*Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.*

| Rank | Company | Percentile | Letter | Warnings |
|---|---|---|---|---|
| 100 | Staar Surgical Co. (STAA) | 26.8 | B | |
| 101 | Travere Therapeutics, Inc. (TVTX) | 27.1 | B | |
| 102 | Tela Bio, Inc. (TELA) | 27.4 | B | fortress balance sheet |
| 103 | Avalo Therapeutics, Inc. (AVTX) | 27.6 | B | dilution, degenerate inputs |
| 104 | Alphatec Holdings, Inc. (ATEC) | 27.9 | B | |
| 105 | Agape ATP Corp. (ATPC) | 28.2 | B | late filer |
| 106 | Myriad Genetics Inc. (MYGN) | 28.5 | B | fortress balance sheet |
| 107 | DocGo Inc. (DCGO) | 28.7 | B | late filer, fortress balance sheet |
| 108 | Agios Pharmaceuticals, Inc. (AGIO) | 29.0 | B | short runway |
| 109 | Healthcare Services Group Inc. (HCSG) | 29.3 | B | |
| 110 | Cadre Holdings, Inc. (CDRE) | 29.5 | B | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

## What the price implies

*at the 2026-11-03 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | (96.6%) | (2.1%) | 1 |
| Distance from 52-week high | (98.1%) | (30.4%) | 0 |
| EBIT to enterprise value | not computable | (1.5%) | |
| Free cash flow yield | (65.8%) | (1.0%) | 10 |
| Book value to price | 17.08 | 0.29 | 99 |
| Sales to price | 1.18 | 0.30 | 85 |
| Composite equity issuance, five years | not computable | 21.4% | |
| Relative strength against the sector, log excess return | (3.54) | (0.19) | 1 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | fail |
| Operating cash flow exceeds net income | fail |
| Long-term leverage fell | fail |
| Current ratio improved | pass |
| No new shares issued | fail |
| Gross margin improved | fail |
| Asset turnover improved | pass |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $45,480 |
| Operating cash flow, four quarters | -$970,178 |
| Months of runway | not finite |
| Days since last periodic filing | 84 (10-Q received Aug 14, 2026) |
| Median daily dollar volume, 63 sessions | $33,440 |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | gross profit | us-gaap:GrossProfit | $838,270 | 2025-12-31 | 2026-04-13 | 10-K | 26-016297 |
| 2 | assets | us-gaap:Assets | $24.6M | 2025-12-31 | 2026-04-13 | 10-K | 26-016297 |
| 3 | net income | us-gaap:NetIncomeLoss | -$2.3M | 2025-12-31 | 2026-04-13 | 10-K | 26-016297 |
| 4 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$2.4M | 2025-12-31 | 2026-04-13 | 10-K | 26-016297 |
| 5 | assets | us-gaap:Assets | $3.2M | 2024-12-31 | 2026-04-13 | 10-K | 26-016297 |
| 6 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $1.5M | 2025-12-31 | 2026-04-13 | 10-K | 26-016297 |
| 7 | gross profit | us-gaap:GrossProfit | $759,148 | 2024-12-31 | 2026-04-13 | 10-K | 26-016297 |
| 8 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $1.3M | 2024-12-31 | 2026-04-13 | 10-K | 26-016297 |
| 9 | gross profit | us-gaap:GrossProfit | $936,572 | 2023-12-31 | 2025-03-31 | 10-K | 25-001611 |
| 10 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $1.4M | 2023-12-31 | 2025-03-31 | 10-K | 25-001611 |
| 11 | gross profit | us-gaap:GrossProfit | $1.2M | 2022-12-31 | 2024-04-01 | 10-K | 24-012467 |
| 12 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $1.9M | 2022-12-31 | 2024-04-01 | 10-K | 24-012467 |
| 13 | gross profit | us-gaap:GrossProfit | $719,629 | 2021-12-31 | 2023-03-31 | 10-K | 23-010029 |
| 14 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $1.0M | 2021-12-31 | 2023-03-31 | 10-K | 23-010029 |
| 15 | current assets | us-gaap:AssetsCurrent | $24.3M | 2025-12-31 | 2026-04-13 | 10-K | 26-016297 |
| 16 | current liabilities | us-gaap:LiabilitiesCurrent | $2.1M | 2025-12-31 | 2026-04-13 | 10-K | 26-016297 |
| 17 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$11.8M | 2025-12-31 | 2026-04-13 | 10-K | 26-016297 |
| 18 | operating income | us-gaap:OperatingIncomeLoss | -$3.3M | 2025-12-31 | 2026-04-13 | 10-K | 26-016297 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| 19 | book equity | us-gaap:StockholdersEquity | $22.5M | 2025-12-31 | 2026-04-13 | 10-K | 26-016297 |
| 20 | liabilities | us-gaap:Liabilities | $2.2M | 2025-12-31 | 2026-04-13 | 10-K | 26-016297 |
| 21 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $3,959 | 2021-12-31 | 2022-07-05 | 10-K/A | 22-018503 |
| 22 | depreciation amortization | us-gaap:Depreciation | $75,797 | 2021-12-31 | 2023-03-31 | 10-K | 23-010029 |
| 23 | operating income | us-gaap:OperatingIncomeLoss | -$1.9M | 2021-12-31 | 2023-03-31 | 10-K | 23-010029 |
| 24 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | -$2.4M | 2021-12-31 | 2023-03-31 | 10-K | 23-010029 |
| 25 | income tax | us-gaap:IncomeTaxExpenseBenefit | $137,067 | 2021-12-31 | 2023-03-31 | 10-K | 23-010029 |
| 26 | current assets | us-gaap:AssetsCurrent | $3.9M | 2021-12-31 | 2023-03-31 | 10-K | 23-010029 |
| 27 | current liabilities | us-gaap:LiabilitiesCurrent | $1.3M | 2021-12-31 | 2023-03-31 | 10-K | 23-010029 |
| 28 | current assets | us-gaap:AssetsCurrent | $5.7M | 2020-12-31 | 2022-07-05 | 10-K/A | 22-018503 |
| 29 | current liabilities | us-gaap:LiabilitiesCurrent | $1.0M | 2020-12-31 | 2022-07-05 | 10-K/A | 22-018503 |
| 30 | assets | us-gaap:Assets | $5.7M | 2023-12-31 | 2025-03-31 | 10-K | 25-001611 |
| 31 | assets | us-gaap:Assets | $2.8M | 2022-12-31 | 2024-04-01 | 10-K | 24-012467 |
| 32 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 1,000,626 | 2026-03-17 | 2026-04-13 | 10-K | 26-016297 |
| 33 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 50,005,381 | 2025-03-28 | 2025-03-31 | 10-K | 25-001611 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.